On Monday, February 24, 2025, OFA filed a lawsuit against FDA in Fort Worth Texas over FDAs decision to remove semaglutide from the drug shortage list
Cagrilintide + Tirzepatide vs CagriSema vs Cagrilintide + Retatrutide The two most common alternatives are CagriSema (the evidence-backed combination of cagrilintide + semaglutide) and cagrilintide + retatrutide (a broader but more speculative option)
Retatrutide appears on neither, which leaves zero compliant pathway
Elevated NAD+ promotes mitochondrial biogenesis and function, improving cellular energy metabolism through enhanced oxidative phosphorylation
Once the necessary information is received, Blue Cross Blue Shield will then review the request for authorization
Weight loss drugs have exploded into the public spotlight in the U.S., particularly after the FDA approved Wegovy for weight loss in 2021